In 2012, sales were buoyant at WACKER BIOSOLUTIONS, up 9.1 percent to €157.6 million (2011: €144.5 million). Higher volumes and positive exchange-rate effects fueled the increase. With the exception of biopharmaceuticals, every business area generated growth. Regionally, the largest gain of 34 percent was achieved in Germany. In Europe and the Americas, sales climbed more than 10 percent in each region. Sales in Asia grew slightly.
EBITDA also performed strongly, rising by as much as 20.1 percent to €24.5 million (2011: €20.4 million) amid higher volumes and exchange-rate effects. The EBITDA margin increased to 15.5 percent (2011: 14.1 percent).
Investments over Double Prior-Year Figure
Investments more than doubled compared with a year earlier, reaching €19.3 million (2011: €8.6 million). The largest share of the funding went on constructing a new plant for polyvinyl acetate solid resins, which are used in the production of gumbase. With an annual capacity of 20,000 metric tons, the plant is being built at our Nanjing site (China). It will replace our former production site at Wuxi.
The number of employees at WACKER BIOSOLUTIONS as of December 31, 2012, rose to 357 (December 31, 2011: 354).
| Download XLS |
|
Key Data: WACKER BIOSOLUTIONS | ||||||||||||||
|
|
|
|
|
|
|
|
| |||||||
|
€ million |
2012 |
2011 |
2010 |
2009 |
2008 |
2007 |
2006 | |||||||
|
|
|
|
|
|
|
|
| |||||||
|
Total sales |
157.6 |
144.5 |
142.4 |
104.9 |
97.7 |
112.4 |
112.6 | |||||||
|
EBITDA |
24.5 |
20.4 |
25.0 |
9.9 |
9.2 |
9.5 |
10.5 | |||||||
|
17.8 |
13.3 |
16.6 |
4.7 |
6.0 |
-7.5 |
-4.5 | ||||||||
|
Investments (asset additions) |
19.3 |
8.6 |
6.5 |
12.7 |
16.5 |
7.5 |
4.0 | |||||||
|
R&D costs |
6.6 |
6.2 |
3.5 |
4.4 |
2.3 |
2.1 |
6.0 | |||||||
|
Employees (December 31, number) |
357 |
354 |
363 |
344 |
259 |
245 |
300 | |||||||